| pubmed-article:8105762 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8105762 | lifeskim:mentions | umls-concept:C0379900 | lld:lifeskim |
| pubmed-article:8105762 | lifeskim:mentions | umls-concept:C0023688 | lld:lifeskim |
| pubmed-article:8105762 | lifeskim:mentions | umls-concept:C0075025 | lld:lifeskim |
| pubmed-article:8105762 | lifeskim:mentions | umls-concept:C0871161 | lld:lifeskim |
| pubmed-article:8105762 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:8105762 | pubmed:dateCreated | 1993-11-16 | lld:pubmed |
| pubmed-article:8105762 | pubmed:abstractText | The 5-HT1A ligand, spiroxatrine, displays very low affinity for alpha 1-adrenergic binding sites and a relatively high affinity for alpha 2-adrenergic binding sites. Nonetheless, recent functional studies indicate that spiroxatrine is a potent antagonist of the alpha 1-adrenoceptor mediating contraction in the rat isolated aorta. On the basis of the widely studied heterogeneous interaction of drugs with alpha-adrenoceptors in several experimental models, the present study was designed to analyze the alpha-adrenoceptor antagonist properties of spiroxatrine in the pithed rat. Animals were prepared for recording of arterial blood pressure and intravenous (i.v.) administration of drugs. Norepinephrine and the alpha 1- and alpha 2- adrenoceptor agonists methoxamine and clonidine, respectively, elicited pressor responses in a dose-related fashion. Spiroxatrine (1 mg/kg, i.v.) produced a moderate--but significant--rightward displacement of the dose-response curves to all agonists. The present data lead us to suggest that, though spiroxatrine exhibits alpha 1- and alpha 2-adrenoceptor antagonist properties in the pithed rat, its potency does not seem to correlate with that found in rat aorta. The potential involvement of alpha 1-adrenoceptor subtypes is discussed. | lld:pubmed |
| pubmed-article:8105762 | pubmed:language | spa | lld:pubmed |
| pubmed-article:8105762 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8105762 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8105762 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8105762 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8105762 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8105762 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8105762 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8105762 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8105762 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8105762 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8105762 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8105762 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8105762 | pubmed:issn | 0020-3785 | lld:pubmed |
| pubmed-article:8105762 | pubmed:author | pubmed-author:HongEE | lld:pubmed |
| pubmed-article:8105762 | pubmed:author | pubmed-author:VillalónC MCM | lld:pubmed |
| pubmed-article:8105762 | pubmed:author | pubmed-author:IbarraMM | lld:pubmed |
| pubmed-article:8105762 | pubmed:author | pubmed-author:RansanzVV | lld:pubmed |
| pubmed-article:8105762 | pubmed:author | pubmed-author:TerrónJ AJA | lld:pubmed |
| pubmed-article:8105762 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8105762 | pubmed:volume | 63 | lld:pubmed |
| pubmed-article:8105762 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8105762 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8105762 | pubmed:pagination | 289-95 | lld:pubmed |
| pubmed-article:8105762 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:8105762 | pubmed:meshHeading | pubmed-meshheading:8105762-... | lld:pubmed |
| pubmed-article:8105762 | pubmed:meshHeading | pubmed-meshheading:8105762-... | lld:pubmed |
| pubmed-article:8105762 | pubmed:meshHeading | pubmed-meshheading:8105762-... | lld:pubmed |
| pubmed-article:8105762 | pubmed:meshHeading | pubmed-meshheading:8105762-... | lld:pubmed |
| pubmed-article:8105762 | pubmed:meshHeading | pubmed-meshheading:8105762-... | lld:pubmed |
| pubmed-article:8105762 | pubmed:meshHeading | pubmed-meshheading:8105762-... | lld:pubmed |
| pubmed-article:8105762 | pubmed:meshHeading | pubmed-meshheading:8105762-... | lld:pubmed |
| pubmed-article:8105762 | pubmed:meshHeading | pubmed-meshheading:8105762-... | lld:pubmed |
| pubmed-article:8105762 | pubmed:meshHeading | pubmed-meshheading:8105762-... | lld:pubmed |
| pubmed-article:8105762 | pubmed:meshHeading | pubmed-meshheading:8105762-... | lld:pubmed |
| pubmed-article:8105762 | pubmed:meshHeading | pubmed-meshheading:8105762-... | lld:pubmed |
| pubmed-article:8105762 | pubmed:meshHeading | pubmed-meshheading:8105762-... | lld:pubmed |
| pubmed-article:8105762 | pubmed:meshHeading | pubmed-meshheading:8105762-... | lld:pubmed |
| pubmed-article:8105762 | pubmed:meshHeading | pubmed-meshheading:8105762-... | lld:pubmed |
| pubmed-article:8105762 | pubmed:meshHeading | pubmed-meshheading:8105762-... | lld:pubmed |
| pubmed-article:8105762 | pubmed:meshHeading | pubmed-meshheading:8105762-... | lld:pubmed |
| pubmed-article:8105762 | pubmed:articleTitle | [The alpha-antiadrenergic properties of spiroxatrine, a ligand of serotonergic 5-HT1A receptors]. | lld:pubmed |
| pubmed-article:8105762 | pubmed:affiliation | Departamento de Farmacología y Toxicología, Centro de Investigación y de Estudios Avanzados, Instituto Politécnico Nacional, México, D.F. | lld:pubmed |
| pubmed-article:8105762 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8105762 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:8105762 | pubmed:publicationType | English Abstract | lld:pubmed |
